Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab by Kirsten Minden et al.
POSTER PRESENTATION Open Access
Administration of routine preventative
vaccinations in children with polyarticular
juvenile idiopathic arthritis receiving adalimumab
Kirsten Minden1*, Mahinda Karunaratne2, Hartmut Kupper3, Jasmina Kalabic3
From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014
Introduction
Adalimumab (ADA) has been shown to be safe and
effective in polyarticular juvenile idiopathic arthritis
(pJIA), and is approved for use in moderate to severe
pJIA patients (pts) ≥4 years (yrs) in the US, Australia,
and Japan, and in the EU for pts ≥2 yrs.
Objectives
This post hoc report describes the observed use of vac-
cines in pJIA pts receiving ADA in 3 clinical trials and
one registry.
Methods
Pts with active pJIA were enrolled in one of the following
trials: M10-444 (ages 2 to <4 or ≥4 weighing <15 kg in
US, EU), M10-240 (ages 4-17 in Japan), DE038 (ages 4-17
in US, EU) or the STRIVE (P10-262) registry (ages 4-17
in US, EU, and Australia). Pts received ADA±methotrex-
ate. Vaccinations were administered based on the judg-
ment of the study investigator or the treating physician.
Descriptive statistics were used to summarize all vaccina-
tions. Adverse events (AEs) related to active influenza
virus infection events occurring within 270 days after
influenza vaccination were collected by a predefined
MedDRA query 15.1 [Lack of efficacy/effect Influenza
(Vaccination Product Specific)].
Results
The influenza vaccine was the most frequently adminis-
tered: 55, 63, 10 and 22 influenza vaccines were admi-
nistered in DE038, M10-240, M10-444 and P10-262,
respectively. In addition, pneumococcal, human
papilloma virus, diphtheria, tetanus and/or pertussis,
hepatitis A and B, and polio vaccines were administered.
2 pts each received >5 vaccinations in DE038 and M10-
240, while 3 pts each in M10-444 and P10-262 received
>1 but <5 vaccinations. The influenza vaccine was admi-
nistered to 32/171 (19%), 20/25 (80%), 6/32 (19%) and
21/533 (4%) of pts during the course of the study in
DE038, M10-240, M10-444 and P10-262 respectively,
and the mean (SD) time to 1st influenza vaccination
while pts were on ADA was high: 675 (618), 189 (80),
93 (90) and 443 (396) days. The rates of influenza-
related AEs reported for pts who received influenza vac-
cinations and those who did not were: 13% vs 9% for
DE038, 15% vs 20% for M10-240, 0% vs 12% for M10-
444, and 5% vs 0.4% for P10-262. Table 1.
Conclusion
These data support the idea that pJIA pts treated with
ADA can be immunized with routine, inactive, preventa-
tive vaccines. Not all of the eligible pts were vaccinated
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Table 1






Total patients vaccinated, n/N 38/171 20/25 6/32 22/533






Total vaccinations, n 77 64 10 25
Patients with >1 type of
vaccination, n
11 1 0 2
Different types of vaccinations, n 9 2 1 4
Mean time to 1st vaccination*,
days
688 189 93 448
Mean age at 1st vaccination*, yrs 12.9 14.0 3.6 12.0
*while on ADA
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on time according to the Centers of Disease Control
(CDC) recommendations, and many pts were not vacci-
nated at all, suggesting that physicians may be reluctant
to use vaccines in children receiving antirheumatic
therapies. Further investigation of vaccination practices
for pts with JIA is warranted.
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